3-[4-羟基-3-[5,6,7,8-四氢-5,5,8,8-四甲基-3-(戊氧基)-2-萘基]苯基]-2-丙酸 | 847239-17-2

• 物质功能分类: 催化剂及助剂 - 紫外线吸收剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-[4-羟基-3-[5,6,7,8-四氢-5,5,8,8-四甲基-3-(戊氧基)-2-萘基]苯基]-2-丙酸
• 中文别名: 3-[4-羟基-3-[5,6,7,8-四氢-5,5,8,8-四甲基-3-(戊基氧基)-2-萘]苯基]-2-丙酸
• 英文名称: (2E)-3-{4-hydroxy-3-[5,5,8,8-tetramethyl-3-(pentyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl]phenyl}prop-2-enoic acid
• 英文别名: (E)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
• CAS: 847239-17-2
• 化学式: C₂₈H₃₆O₄
• 分子量: 436.6
• InChiKey: APJSHECCIRQQDV-ZRDIBKRKSA-N

物化性质

• 溶解度：
  DMF：25mg/mL； DMSO：15mg/mL；乙醇：20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

UVI 3003 是一种高度选择性的 retinoid X receptor (RXR) 抑制剂，在 Cos7 细胞中，抑制非洲爪蟾蜍和人 RXRα 的活性，IC50 值分别为 0.22 和 0.24 μM。

靶点

IC50: 0.22 μM (Xenopus RXRα, in Cos7 cells), 0.24 μM (Human RXRα, in Cos7 cells)

体外研究

UVI3003 inhibits the activity of xenopus and human RXRα, with IC ₅₀ s of 0.22 and 0.24 μM, respectively. UVI3003 fully activates xPPARγ with an EC ₅₀ of 12.6 μM, and is almost completely inactive on hPPARγ and mPPARγ. UVI 3003 (10 μM) does not change the proliferation rate of extraocular muscles (EOM)-derived or LEG-derived EECD34 cells. UVI 3003 causes a 65.4% difference in EECD34 cell fusion and desmin expression.

文献信息

• Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：IO Therapeutics, Inc.

  公开号：US10004709B2

  公开（公告）日：2018-06-26

  Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

  本文公开了治疗癌症的方法，包括施用至少一种免疫检查点抑制剂和至少一种维甲酸受体或维甲酸 X 受体活性剂。
• Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
  申请人：Io Therapeutics, Inc.

  公开号：US10471030B2

  公开（公告）日：2019-11-12

  Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.

  本文公开了治疗癌症的方法，包括给药 CAR 修饰的免疫细胞和至少一种视黄酸受体和/或视黄醇 X 受体活性剂。
• Heterocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US10905768B1

  公开（公告）日：2021-02-02

  This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了能与 E3 泛素连接酶（通常是通过脑龙）（"Degrons"）结合的杂环化合物，这些杂环化合物可用于治疗目的或与选定靶蛋白的靶向配体相连接，并提供了其使用方法和组合物及其制备方法。
• Spirocyclic degronimers for target protein degradation
  申请人：C4 Therapeutics, Inc.

  公开号：US11185592B2

  公开（公告）日：2021-11-30

  This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

  本发明提供了具有螺环 E3 泛素连接酶靶向基团（Degrons）的化合物，这些化合物可单独使用，也可与用于体内降解的蛋白质的靶向配体连接，本发明还提供了其使用方法和组合物及其制备方法。
• Method of identifying novel protein aggregation inhibitors based on chemical kinetics
  申请人：Cambridge Enterprise Limited

  公开号：US11536729B2

  公开（公告）日：2022-12-27

  The subject matter disclosed herein relates to methods of identifying pharmacophores and inhibitors against protein aggregation. The present disclosure also provides pharmacophores themselves and medical uses of agents in the treatment of diseases associated with protein aggregation.

  本文公开的主题涉及鉴定抗蛋白质聚集的药剂和抑制剂的方法。本公开内容还提供了药剂本身以及药剂在治疗与蛋白质聚集有关的疾病方面的医学用途。